Minnetonka, MN – MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, and Prairie Education & Research Cooperative (PERC), an organization specializing in cardiovascular and vascular trial management, core lab, and continuing medical education services, are pleased to announce that PERC has joined the iMedNetTM CRO Partner Program. PERC will leverage iMedNet EDC, MedNet’s innovative cloud‐based eClinical technology platform, to easily and cost‐effectively build and manage their customers’ clinical research studies.
“iMedNet EDC provides an ideal electronic data capture solution that is financially feasible for PERC’s budget sensitive companies while maintaining a high level of functionality and flexibility,” stated Cynthia Deitrick, Chief Operating Officer at PERC. “PERC looks forward to future business opportunities where iMedNet can be utilized as a seamless solution for clinical trial sponsors.”
“MedNet is honored to be working with PERC-a top quality, highly‐respected clinical services organization,” noted Brian Sweeney, Vice President of Business Development at MedNet Solutions. “We’re confident that iMedNet EDC will provide the effective and reliable technology infrastructure they need for years to come.”
Please contact MedNet Solutions for more information on iMedNet EDC or the iMedNet CRO Partner Program, and PERC for additional details on their cardiovascular and vascular clinical services.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.